MedTrace Logo

Cardiovascular Disease Risk in Women With Endometriosis

NCT03746535 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-05-23

No results posted yet for this study

Summary

To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.

Conditions

  • Endometriosis

Interventions

DRUG

Elagolix

Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Nina Stachenfeld, MD · Yale University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2025-12-01
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03746535 on ClinicalTrials.gov